酸素療法の世界市場規模：製品別、携帯性別、用途別、地域別、予測

酸素療法の市場規模と予測

酸素療法の市場規模は2024年に160億7,000万米ドルと評価され、2026～2032年にかけてCAGR 11.45%で成長し、2032年には382億6,000万米ドルに達すると予測されます。

酸素療法は、呼吸困難や血中酸素濃度が低い人に酸素を投与する治療法です。酸素療法は、鼻カニューレ、フェイスマスク、人工呼吸器など、さまざまな機器を使って行われます。

酸素療法は、慢性閉塞性肺疾患（COPD）、肺炎、喘息、心不全の治療や、手術中の適切な酸素補給に用いられます。

さらに、血中酸素飽和度を向上させ、息切れや疲労感などの症状を軽減し、重症の呼吸器疾患や心疾患の患者を安定化させサポートするために、クリティカルケア環境では不可欠です。

世界の酸素療法市場力学

酸素療法市場を形成している主な市場力学は以下の通り：

主な市場促進要因

呼吸器疾患の有病率の増加：慢性呼吸器疾患の有病率の増加は、酸素療法市場の重要な促進要因です。世界保健機関（WHO）によると、慢性閉塞性肺疾患（COPD）は2019年に世界で3億9,100万人に影響を与えました。COPDは世界で3番目に大きな死因であり、2019年には323万人が死亡しています。米国肺協会によると、2020年には3,730万人のアメリカ人（成人の11.5％）が慢性肺疾患に罹患するといいます。喘息は2,500万人のアメリカ人が罹患しており、そのうち510万人が子供です。

人口の高齢化：世界人口の高齢化に伴い、酸素療法の需要は増加すると予測されています。国連経済社会局の報告によると、65歳以上の人口は2050年までに15億人に達する見込みです。2050年までに、世界の6人に1人が65歳以上となり、2019年の11人に1人から増加します。米国国勢調査局によると、過去10年間で米国の65歳以上人口は3分の1以上（34.2％）増加しました。2030年にはベビーブーム世代がすべて65歳以上になり、高齢者人口は住民の5人に1人に増加します。

酸素供給システムの技術的進歩：携帯型および家庭用酸素療法機器の技術革新が市場拡大を後押ししています。米国食品医薬品局（FDA）によると、2015～2020年の間に50以上の新しい酸素療法機器または既存機器の大幅な改良が認可されました。Respiratory Care誌に掲載された研究では、長期酸素療法を受けているメディケア受給者のうち、携帯型酸素濃縮器の使用率が2009年の11.5%から2018年には43.5%に増加していることが判明しました。

主な課題

高コスト：酸素濃縮器、ボンベ、補充剤、消耗品によって患者の資金は枯渇します。この経済的負担は、必要な治療を先延ばしにしたり、スキップしたりする原因となり、健康状態を悪化させます。ヘルスケア資源が限られている地域では、不十分なインフラと補助金の不足が、安価な酸素療法へのアクセスを妨げています。

償還の課題：酸素治療の償還方針は複雑で、支払者、患者の状態、機器によって異なります。この一貫性の欠如が承認プロセスを複雑にし、保険適用を遅らせ、患者の転帰に悪影響を及ぼします。膨大な書類作成要件と正確な保険適用制限があいまいさを生み、医療提供者が酸素治療サービスの計画と予算を立てることを困難にし、市場の成長を制限しています。

主要動向

在宅ケアへのシフト：ポータブル濃縮器と遠隔モニタリング技術の開発により、酸素療法市場は在宅ケアへと移行しつつあります。この移行により、病院での再入院が減少し、患者中心のアプローチが奨励されるため、患者が自宅で酸素療法を受けることが容易になり、費用も抑えられます。

遠隔医療の統合：遠隔医療は、患者のバイタル、酸素濃度、治療のアドヒアランスを遠隔でモニタリングできるため、酸素治療管理においてますます重要になってきています。問題の早期発見と遠隔相談により、専門家による治療へのアクセスが向上し、問題が解決されるため、患者の転帰が改善され、結果も少なくなります。

快適性と利便性の重視：市場は、使いやすく快適な酸素供給システムを優先しています。患者の快適性と利便性を高め、酸素療法を必要とする患者の治療アドヒアランスとQOLを向上させるために、より軽量で静かで目立たない濃縮器とマスクが開発されています。

目次

第1章 イントロダクション

• 市場の導入
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 市場概要

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 酸素療法市場：製品別

• 概要
• 酸素源装置
  • 心臓血管・胸部外科用酸素療法機器
  • 酸素濃縮器
  • 液体酸素
  • 酸素ボンベ
• 酸素供給装置
  • 酸素マスク
  • 鼻カニューラ
  • ベンチュリーマスク
  • ノンリブリーザーマスク
  • バッグバルブマスク
• その他

第6章 酸素療法市場：携帯性別

• 概要
• 据置型
• 携帯型

第7章 酸素療法市場：用途別

• 概要
• 慢性閉塞性肺疾患
• 喘息
• 閉塞性睡眠時無呼吸症候群
• 呼吸困難症候群
• 嚢胞性線維症
• 肺炎
• その他

第8章 酸素療法市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 競合情勢

• 概要
• 各社の市場ランキング
• 主な発展戦略

第10章 企業プロファイル

• Linde plc
• Chart Industries, Inc.
• Invacare Corporation
• Philips Respironics
• Inogen, Inc
• DeVilbiss Healthcare LLC
• Fisher & Paykel Healthcare Limited
• Drive DeVilbiss Healthcare
• GCE Group
• Taiyo Nippon Sanso Corporation.

第11章 主な発展

• 製品上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第12章 付録

• 関連調査

Oxygen Therapy Market Size And Forecast

Oxygen Therapy Market size was valued at USD 16.07 Billion in 2024 and is projected to reach USD 38.26 Billion by 2032, growing at a CAGR of 11.45% from 2026 to 2032.

Oxygen therapy is a medical treatment that involves administering oxygen to individuals with difficulty breathing or low blood oxygen levels. It is given via various devices, including nasal cannulas, face masks, and ventilators.

Oxygen therapy is used to treat chronic obstructive pulmonary disease (COPD), pneumonia, asthma, and heart failure and to provide proper oxygenation during surgery.

Furthermore, it improves blood oxygen saturation, reducing symptoms such as shortness of breath and exhaustion, and is vital in critical care settings for stabilizing and supporting patients with severe respiratory or cardiac problems.

Global Oxygen Therapy Market Dynamics

The key market dynamics that are shaping the oxygen therapy market include:

Key Market Drivers

Increasing Prevalence of Respiratory Diseases: The increased prevalence of chronic respiratory disorders is a significant driver of the oxygen therapy market. According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) impacted 391 million individuals worldwide in 2019. COPD is the world's third greatest cause of death, with 3.23 million deaths in 2019. According to the American Lung Association, 37.3 million Americans (11.5% of adults) suffered from chronic lung disease in 2020. Asthma affects 25 million Americans, with 5.1 million children.

Aging Population: As the world's population ages, demand for oxygen therapy is predicted to rise. The United Nations Department of Economic and Social Affairs reported that the number of people aged 65 and over is expected to reach 1.5 billion by 2050. By 2050, 1 in 6 individuals worldwide will be above the age of 65, up from 1 in 11 in 2019. The United States Census Bureau reports that over the last decade, the U.S. population aged 65 and over increased by more than a third (34.2%). By 2030, all baby boomers will be 65 or older, increasing the elderly population to one in every five residents.

Technological Advancements in Oxygen Delivery Systems: Innovations in portable and home-based oxygen therapy equipment are propelling market expansion. According to the United States Food and Drug Administration (FDA), more than 50 new oxygen therapy devices or significant modifications to existing devices were authorized between 2015 and 2020. A study published in the journal Respiratory Care discovered that the usage of portable oxygen concentrators increased from 11.5% in 2009 to 43.5% in 2018 among Medicare beneficiaries getting long-term oxygen therapy.

Key Challenges:

High Costs: Oxygen therapy is expensive, especially for long-term care, with concentrators, cylinders, refills, and supplies depleting patient funds. This financial burden causes people to postpone or skip necessary treatment, lowering health outcomes. In regions with limited healthcare resources, insufficient infrastructure and a lack of subsidies impede access to inexpensive oxygen therapy.

Reimbursement Challenges: Oxygen treatment reimbursement policies are complex and vary depending on the payer, patient condition, and equipment. This lack of consistency complicates the approval process, which delays coverage and has a negative impact on patient outcomes. Extensive paperwork requirements and precise coverage limitations generate ambiguity, making it difficult for providers to plan and budget for oxygen treatment services, thus limiting market growth.

Key Trends:

Shift Towards Home-Based Care: The oxygen therapy market is shifting toward home-based care, thanks to developments in portable concentrators and remote monitoring technology. This transition decreases hospital readmissions and encourages a patient-centered approach, making it easier and less expensive for patients to get oxygen therapy at home.

Telemedicine Integration: Telemedicine is becoming increasingly important in oxygen treatment management since it allows for remote monitoring of patient vitals, oxygen levels, and therapy adherence. Early problem detection and teleconsultations improve access to specialist treatment and resolve problems, resulting in better patient outcomes and fewer consequences.

Focus on Comfort and Convenience: The market prioritizes oxygen delivery systems that are easy to use and pleasant. Lighter, quieter, and more inconspicuous concentrators and masks are being developed to increase patient comfort and convenience and to increase treatment adherence and quality of life for patients requiring oxygen therapy.

Global Oxygen Therapy Market Regional Analysis

Here is a more detailed regional analysis of the oxygen therapy market:

North America:

According to Verified Market Research, North America is estimated to dominate during the forecast period. Chronic respiratory disorders are a major driver of oxygen therapy in North America, especially in the United States. According to the Centers for Disease Control and Prevention (CDC), 16.5 million persons in the United States (6.4%) were diagnosed with COPD in 2019. Asthma affects approximately 25 million Americans, including 7.7% of adults and 7.5% of children. The American Lung Association reports that COPD is the fourth biggest cause of death in the United States. The entire cost of COPD in the United States is expected to reach USD 49 Billion in 2020, with USD 32.1 Billion in direct medical costs.

Furthermore, the elderly population in North America is driving the demand for oxygen therapy. Statistics Canada provides the following information: In 2021, more than 7 million Canadians were 65 and older, accounting for 19% of the total population. This number is predicted to increase to 9.7 million by 2030, accounting for roughly 23% of Canada's population. According to the United States Census Bureau, the number of Americans aged 65 and over is expected to nearly double, from 52 million in 2018 to 95 million in 2060. During this time, the proportion of people aged 65 and up will increase from 16% to 23% of the total population.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. Air pollution is a major concern in many Asian Pacific countries, resulting in an increase in respiratory disorders and a greater demand for oxygen therapy. According to the World Health Organization (WHO), 9 out of every 10 persons in the Asia Pacific region are exposed to air pollution levels that represent a serious health risk. In 2019, air pollution was the cause of 4.2 million premature deaths in the region. According to the Health Effects Institute's State of Global Air 2020 study, air pollution caused 1.67 million fatalities in India in 2019 and 1.85 million deaths in China. These two countries accounted for roughly 60% of global air pollution-related deaths.

Furthermore, the Asia Pacific region's population is rapidly aging, driving up the need for oxygen therapy. According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), the number of elderly people (aged 65 and more) in Asia and the Pacific is predicted to more than double, from 651 million in 2020 to around 1.3 billion by 2050. By 2050, roughly a quarter of the region's population will be over the age of 65. Japan, which has the region's fastest-aging population, serves as a stark illustration. According to the Japan Statistics Bureau, 28.7% of Japan's population was 65 and over in September 2020. This percentage is expected to rise to 35.3% by 2040.

Global Oxygen Therapy Market: Segmentation Analysis

The Oxygen Therapy Market is segmented on the basis of Product, Portability, and Application.

Oxygen Therapy Market, Product

Oxygen Source Equipment

Oxygen Therapy Equipment for Cardiovascular & Thoracic Surgeries

Oxygen Concentrators

Liquid Oxygen

Oxygen Cylinders

Oxygen Delivery Devices

Oxygen Maska

Nasal Cannulas

Venturi Masks

Non-Rebreather Masks

Bag-Valve Masks

Others

Based on Product, the market is segmented into Oxygen Source Equipment and Oxygen Delivery Devices. The oxygen source equipment segment is estimated to dominate the oxygen therapy market. Oxygen concentrators, which are the primary source of oxygen delivery in a variety of situations, serve as the foundation of oxygen therapy. The rising prevalence of chronic respiratory disorders demands a steady and dependable supply of oxygen, which oxygen concentrators and other source equipment deliver. While delivery devices such as masks and cannulas are required for oxygen administration, they are considered secondary parts that rely on oxygen source equipment to work. This reliance on oxygen source equipment for key functions underpins its market dominance.

Oxygen Therapy Market, By Portability

• Stationary
• Portable

Based on Portability, the oxygen therapy market is divided into Stationary and Portable. The portability segment is estimated to dominate the market over the forecast period due to technology improvements that have resulted in lightweight, user-friendly portable oxygen concentrators that allow patients to live active lives while getting supplementary oxygen. The growing need for home-based care, driven by an older population and rising healthcare expenses, adds to the desire for portable choices. Furthermore, greater knowledge of the benefits of portability, such as improved patient comfort and quality of life, adds to the segment's importance.

Oxygen Therapy Market, By Application

• Chronic Obstructive Pulmonary Disease
• Asthma
• Obstructive Sleep Apnea
• Respiratory Distress Syndrome
• Cystic Fibrosis
• Pneumonia
• Others

Based on Application, the oxygen therapy market is divided into Chronic Obstructive Pulmonary Disease, Asthma, Obstructive Sleep Apnea, Respiratory Distress Syndrome, Cystic Fibrosis, Pneumonia, and Others. The chronic obstructive pulmonary disease segment is estimated to dominate the market over the forecast period. COPD is a common chronic respiratory disorder with an increasing global patient population that needs long-term supplementary oxygen to manage symptoms and improve quality of life. The progressive nature of COPD, which worsens over time, necessitates a greater reliance on oxygen therapy as the disease proceeds. This consistent and increasing demand drives the COPD segment's dominant market share in the oxygen therapy market.

Key Players

• The "Oxygen Therapy Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Linde plc, Chart Industries, Inc., Invacare Corporation, Philips Respironics, Inogen, Inc., DeVilbiss Healthcare LLC, Fisher & Paykel Healthcare Limited, Drive DeVilbiss Healthcare, GCE Group, and Taiyo Nippon Sanso Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Oxygen Therapy Market Recent Developments
• In November 2021, UNICEF collaborated with the UK government and Oxygen Colab to create a reliable oxygen concentrator for use in low-resource situations. This development occurs as an endeavor to combat the Coronavirus crisis and meet the demand for oxygen in critical care settings.
• In July 2021, Belluscura (BELL) signed its first and third distribution agreements for its X-PLO2RTM portable oxygen concentrators with a durable medical equipment manufacturer.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OXYGEN THERAPY MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL OXYGEN THERAPY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL OXYGEN THERAPY MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Oxygen Source Equipment
  • 5.2.1 Oxygen Therapy Equipment for Cardiovascular & Thoracic Surgeries
  • 5.2.2 Oxygen Concentrators
  • 5.2.3 Liquid Oxygen
  • 5.2.4 Oxygen Cylinders
• 5.3 Oxygen Delivery Devices
  • 5.3.1 Oxygen Maska
  • 5.3.2 Nasal Cannulas
  • 5.3.3 Venturi Masks
  • 5.3.4 Non-Rebreather Masks
  • 5.3.5 Bag-Valve Masks
• 5.4 Others

6 GLOBAL OXYGEN THERAPY MARKET, BY PORTABILITY

• 6.1 Overview
• 6.2 Stationary
• 6.3 Portable

7 GLOBAL OXYGEN THERAPY MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Chronic Obstructive Pulmonary Disease
• 7.3 Asthma
• 7.4 Obstructive Sleep Apnea
• 7.5 Respiratory Distress Syndrome
• 7.6 Cystic Fibrosis
• 7.7 Pneumonia
• 7.8 Others

8 GLOBAL OXYGEN THERAPY MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL OXYGEN THERAPY MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Linde plc
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Chart Industries, Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Invacare Corporation
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Philips Respironics
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Inogen, Inc
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 DeVilbiss Healthcare LLC
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Fisher & Paykel Healthcare Limited
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Drive DeVilbiss Healthcare
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 GCE Group
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Taiyo Nippon Sanso Corporation.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research